Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (ALPHA2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04416984 |
|
Recruitment Status :
Recruiting
First Posted : June 4, 2020
Last Update Posted : April 22, 2024
|
Sponsor:
Allogene Therapeutics
Information provided by (Responsible Party):
Allogene Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Genetic: ALLO-501A Biological: ALLO-647 Drug: Fludarabine Drug: Cyclophosphamide | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 160 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) |
| Actual Study Start Date : | May 21, 2020 |
| Estimated Primary Completion Date : | January 2025 |
| Estimated Study Completion Date : | May 2029 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
| Experimental: ALLO-501A, ALLO-647 |
Genetic: ALLO-501A
ALLO-501A is an allogeneic CAR T cell therapy targeting CD19 Biological: ALLO-647 ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen Drug: Fludarabine Chemotherapy for lymphodepletion Drug: Cyclophosphamide Chemotherapy for lymphodepletion |
Primary Outcome Measures :
- Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicities (DLT) at increasing doses of ALLO-501A [ Time Frame: 28 days ]Dose limiting toxicity is defined as protocol-defined ALLO-501A-related adverse events with onset within 28 days following infusion
- Phase 1a: Proportion of subjects experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501A [ Time Frame: 33 days ]DLT is defined as protocol-defined ALLO-647-related adverse events with onset within 33 days following 1st infusion
- Phase 1b: Frequency and severity of ALLO-501A treatment-emergent adverse events (AEs), serious AEs, and AEs of special interest [ Time Frame: Up to 60 months ]
- Phase 2: Overall Response Rate (ORR) assessed per Independent Review Committee (IRC) [ Time Frame: Up to 60 months ]ORR defined as assessment of CR and PR using Lugano classification criteria 2014
Secondary Outcome Measures :
- Phase 1a, 1b, and 2: Duration of Response (DOR) assessed per IRC (Phase 2 only) and per investigator [ Time Frame: Up to 60 months ]DOR is defined only for subjects who experience an objective response and is the time from the first objective response to disease progression or death, whichever comes first per (Cheson et al, 2014)
- Phase 1a, 1b, and 2: Overall Response Rate (ORR) assessed per investigator [ Time Frame: Up to 60 months ]
- Phase 1a, 1b, and 2: Best overall response (CR, PR, SD, PD) assessed per IRC (Phase 2 only) and per investigator [ Time Frame: Up to 60 months ]CR Complete Response, PR Partial Response, SD Stable Disease, PD Progressive Disease
- Phase 1a, 1b, and 2: Progression Free Survival (PFS) assessed per IRC (Phase 2 only) and per investigator [ Time Frame: Up to 60 months ]PFS, defined as time from the enrollment date to progression, relapse, or death
- Phase 1a, 1b, and 2: Time to Response (TTR) assessed per IRC (Phase 2 only) and per investigator [ Time Frame: Up to 60 months ]TTR, defined as the time from the enrollment date to the first observed response
- Phase 1a, 1b, and 2: Overall Survival (OS) [ Time Frame: Up to 60 months ]OS, defined as the time from the enrollment date to death
- Phase 1a, 1b, and 2: Depth of lymphodepletion as assessed by lymphocyte count [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: Duration of lymphodepletion as assessed by lymphocyte recovery [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: Serum concentration of ALLO-647 as measured by microgram per microliter for use in a population PK model [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: ALLO-501A expansion assessed by peak blood concentration (Cmax) [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: ALLO-501A expansion assessed by area under the curve (AUC) [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: ALLO-501A persistence assessed by peak blood concentration (Cmax) [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: ALLO-501A persistence assessed by area under the curve (AUC) [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: Pharmacodynamics will be evaluated on host T cell counts [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: The incidence of anti-drug antibodies against ALLO-501A scFv and/or TALEN® [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: The incidence of anti-drug antibodies against ALLO-647 [ Time Frame: Up to 9 months ]
- Phase 1a, 1b, and 2: Adverse Events (AEs) as characterized by preferred term, frequency, severity timing, seriousness, and relationship to ALLO-501A [ Time Frame: Up to 60 months ]The incidence and severity of Cytokine Release Syndrome (CRS), Graft-Versus-Host Disease (GVHD), infections, cytopenias, and neurotoxicity
- Phase 1a, 1b, and 2: AEs as characterized by preferred term, frequency, severity, timing, seriousness, and relationship to ALLO-647 [ Time Frame: Up to 60 months ]The incidence of infusion-related reactions, cytopenias, and infections
- Phase 1a, 1b, and 2: The incidence and severity of clinically significant laboratory toxicities and relationship to ALLO-647 [ Time Frame: Up to 60 months ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
For subjects with LBCL:
- Histologically confirmed diagnosis of relapsed/refractory large B-cell lymphoma at last relapse per WHO 2017
- At least 1 measurable lesion at time of enrollment
- Relapsed or refractory disease after at least 2 lines of chemotherapy
- Absence of significant donor (product)-specific anti-HLA antibodies (DSA) at screening (Note: Only applicable for Phase 2)
For subjects with CLL/SLL:
- Diagnosis of CLL/SLL
- Relapsed/refractory disease
- Subjects relapsed/refractory to BTKi therapy and high-risk disease
- Subjects relapsed/refractory with 2 or more lines of therapy including BTKi and BCL-2 inhibitor (venetoclax)
- At least 1 measurable lesion at time of enrollment
For all subjects:
- Male or female subjects ≥18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Adequate hematological, renal, and liver function
Exclusion Criteria:
- Active central nervous system (CNS) involvement by malignancy
- Current thyroid disorder (including hyperthyroidism), except for subjects with hypothyroidism controlled on a stable dose of hormone replacement therapy
- Any other active malignancies that required systemic treatment within 3 years prior to enrollment
- Radiation therapy within 2 weeks prior to ALLO-647
- Prior irradiation to >25% of the bone marrow
- Hypocellular bone marrow for age by institutional standard as determined from a bone marrow biopsy performed at time of screening (Note: Only applicable for Phase 2).
- Autologous hematopoietic stem cell transplant (HSCT) within last 6 months (24 weeks)
- Systemic anti-cancer therapy within 2 weeks prior to receiving ALLO-647
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04416984
Contacts
| Contact: Allogene Therapeutics Inc. | 415-604-5696 | clinicaltrials@allogene.com |
Locations
Show 39 study locations
Sponsors and Collaborators
Allogene Therapeutics
| Responsible Party: | Allogene Therapeutics |
| ClinicalTrials.gov Identifier: | NCT04416984 |
| Other Study ID Numbers: |
ALLO-501A-201 |
| First Posted: | June 4, 2020 Key Record Dates |
| Last Update Posted: | April 22, 2024 |
| Last Verified: | April 2024 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Keywords provided by Allogene Therapeutics:
|
CAR T Cell Therapy Allogeneic Cell Therapy Cellular Immuno-therapy AlloCAR T ALLO-501A ALLO-647 LBCL Lymphoma |
Large B-Cell Lymphoma Cema-cel Cemacabtagene ansegedleucel Leukemia Chronic Lymphocytic Leukemia CLL Small Lymphocytic Lymphoma SLL |
Additional relevant MeSH terms:
|
Lymphoma Leukemia Lymphoma, B-Cell Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Hematologic Diseases Lymphoma, Non-Hodgkin Leukemia, B-Cell |
Chronic Disease Disease Attributes Pathologic Processes Cyclophosphamide Fludarabine Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists |